- Holds proprietary technology for protein expression specialized in CHO 바카라 시스템 배팅s
- Secured 41 types of 바카라 시스템 배팅 lines for biopharmaceutical production
[by Sung, Jae Jun] 바카라 시스템 배팅 Biotech, a subsidiary under Huons Group for biopharmaceutical development, is advancing its cell line research and development (R&D) to strengthen its competitiveness in the biopharmaceutical contract development and manufacturing organization (CDMO) market.
Established in 1999 and listed on the KOSDAQ market in 2016, PanGen Biotech has solidified its position as a specialized company in biopharmaceuticals. Since joining the Huons Group in 2024, the company has served as a strategic core for the group’s biopharmaceutical business expansion.
◇Expanding CDMO Business via the Proprietary ‘CHO-TECH’ Platform
PanGen Biotech provides comprehensive biopharmaceutical CDMO services based on its good manufacturing practice (GMP) compliant facilities and core technologies. The company’s core advantage lies in PANGEN CHO-TECH™, essential for biopharmaceutical CDMO. PanGen CHO-TECH™ is a protein expression technology specialized for Chinese Hamster Ovary (CHO) cells, the animal cells used for biopharmaceutical production. It integrates essential technologies for biopharmaceutical development, including the cell line development technology and production process development technology.
PanGen Biotech has leveraged this platform to secure multiple technology transfer agreements and generate royalty income. As partners’ sales increase and development stages advance, PanGen Biotech can expect a virtuous cycle of sales.
◇Secured 41 Types of Bio-Cell Lines, Expanding to Process 바카라 시스템 배팅
A cell line is a clone of living cells capable of continuous proliferation in vitro, making it an essential component for the large-scale production of biopharmaceuticals. Recognizing the strategic importance of cell lines in biopharmaceutical production, 바카라 시스템 배팅 Biotech has successfully established various cell lines and developed production processes based on them, particularly leveraging its proprietary platform technology and expertise to create high-efficiency CHO cell lines. These are vital for maximizing productivity and optimizing quality in biopharmaceutical development.
As of January 2026, 바카라 시스템 배팅 Biotech holds a total of 41 biopharmaceutical production cell lines, including 28 cell lines for therapeutic proteins and 13 cell lines for biosimilar antibodies. Among these, 15 therapeutic protein cell lines and 3 biosimilar antibody cell lines have already completed full production process development. 바카라 시스템 배팅 Biotech aims to complete production process development for approximately 10 biosimilar antibodies including biosimilar antibody cell lines within the next three years.
Upon completion, these biosimilar antibody cell lines offer diverse business opportunities. Beyond internal pipeline development, 바카라 시스템 배팅 Biotech can pursue joint development with domestic and global partners or execute technology licensing to global firms seeking to enter the biosimilar market.
◇Developing Three Blockbuster Biosimilars…Plans to Establish the Process within This Year
Leveraging its proprietary CHO cell line development technololgy, 바카라 시스템 배팅 Biotech is developing biosimilars for three biopharmaceuticals currently sold by multinational pharmaceutical companies.
These are Yervoy (ipilimumab), an immunotherapy drug sold by the U.S. pharmaceutical company Bristol Myers Squibb (BMS); Tremfya (guselkumab), a treatment for autoimmune diseases such as psoriasis by Johnson & Johnson; and Evenity (romosozumab), an osteoporosis treatment by Amgen.
바카라 시스템 배팅 Biotech is already in the process of developing the production cell lines for these three products and plans to complete the development within the year to expand its CDMO business, developing biosimilars as requested by bio-companies and pharmaceutical firms.
According to Grand View Research, a market research agency, the global cell line development market was valued at approximately $5.7 billion (KRW 8.4 trillion) in 2024. The market is projected to reach $13.46 billion (KRW 20 trillion) by 2033, growing at a compound annual growth rate (CAGR) of 10.1%. PanGen Biotech’s continued investment in R&D positions it to capture a significant share of this expanding global market.
◇Growth in EPO Biosimilar Sales and Global Market Expansion
바카라 시스템 배팅 Biotech has reported strong financial performance for the first three quarters of 2025. According to its separate financial statements, the company recorded KRW 10.94 billion in revenue and KRW 1.91 billion in operating profit as of Q3 2025. Compared to the same period last year, revenue increased by 6%, while operating profit surged by 47%. This growth was driven by robust performance across all business sectors, including the sales of its Erythropoietin (EPO) biosimilar and its contract development organization (CDO) services.
The EPO biosimilar business, which is a key growth engine for the sales, is also expanding consistently. Cumulative exports of EPO products have reached approximately KRW 5.72 billion in Q3 2025, a 90% increase from KRW 3 billion in the previous year. Export sales now account for approximately 55% of PanGen Biotech’s total revenue.
바카라 시스템 배팅 Biotech produces and distributes its EPO biosimilar, a treatment for anemia in patients with chronic kidney disease, across multiple domestic and global markets.
PanGen Biotech has received approval from Malaysia’s National Pharmaceutical Regulatory Agency (NPRA) in January 2019; currently marketed under the product name Erysaa. In Korea, the company has received approval from the Ministry of Food and Drug Safety (MFDS) in November 2019; launched as Panpotin in February 2020. To date, the product is approved and sold in six countries, including Korea, Malaysia, the Philippines, Saudi Arabia, Turkiye, and Thailand.
바카라 시스템 배팅 Biotech expects to sustain this upward trajectory by expanding its export footprint further into the Middle East and Africa.
"We will continue to drive financial growth based on our core CHO cell line development technology while maintaining a steady commitment to R&D for future innovation," said Dr. Jaeseung Yoon, CEO of PanGen Biotech. "As a member of the Huons Group, we will strengthen our collaboration and accelerate our strategy to penetrate the global biopharmaceutical market."